Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Survey Finds More Seniors Using Cannabis

The use of cannabis has been increasing among older people as research uncovers more about the impact of the plant’s use among adults. Data from last year’s National Survey of Drug Use and Health shows that the number of adults aged 65 and above who reported recent marijuana use rose by 18%. The survey also found that the number of older individuals who reported that they had used cannabis at some point in their life had increased to 36%, which signals a potential shift in willingness to be more open about prior indulgences.

Individuals with a medical cannabis card in the state of Florida can legally purchase THC products in the state, with those eligible revealing that the process to obtain the card was simple. The process entails taking an eligibility survey to see if one qualifies for medical cannabis in the state. If an individual believes that they qualify, they can then schedule an appointment with qualified medical cannabis doctors.

Before the appointment, patients are advised to get their medical records in order. This especially applies to those who have a prior diagnosis that makes them eligible to use medical cannabis. At the scheduled time and place, patients will be given a recommendation by a physician after their medical records have been reviewed.

After this, they can then complete and submit an application with the state. All applicants have to pay the $75 application fee. The state of Florida usually takes two to four weeks to process the application, after which patients will receive an email on the status of their application.

Trulieve, a marijuana company based in Florida, operates almost 20 dispensaries in the Tampa Bay area. The company, which is one of the leading marijuana providers in the state, gives a 10% discount to consumers aged 55 and above every Sunday.

While the company declined to give data on the total number of its clientele in this age range, its spokesperson revealed that seniors made up a big percentage of registered individuals in the state, noting that the firm had observed a significant increase in the use of marijuana among older people in the last few years.

Additionally, chief marketing officer Valda Coryat stated in an emailed statement that the company had observed that older individuals were receptive to marijuana and its medicinal benefits. Coryat added that in comparison to any other audience, seniors were some of the company’s most passionate and educated users of the medicinal herb.

Given that seniors don’t easily take up unfamiliar habits, the survey results indicating that more seniors are using marijuana is a kind of testament that this demographic is probably benefiting from the medicinal marijuana products manufactured in Florida by companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF).

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Eyeing Q1 2022 Delivery of Highest-Quality Retail Products from Florida Grow Operations

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently completed phase one of an aggressive three-phase development strategy for its Florida facilities, located in Apopka and Sanderson. Phase one entailed the rapid development of the Apopka facility. RWB also announced that it had commenced operation in late September after receiving regulatory approval to begin cultivation. “The initial licensed area in Apopka is capable of producing 85g of flower per plant, translating to projected annual revenue in excess of $10 million. The Apopka facility will supply RWB’s phase two of the strategy, which entails activating thirty 16’ by 40’ customized, self-contained growing pods,” reads a recent article. “We brought this site into production ahead of forecast and ahead of budget, and I’m very proud of our Florida team,” stated RWB CEO Brad Rogers. “Despite being relatively new players in the Florida market, I feel we have the most talented team of PhDs and horticulturalists, and an incredible grow infrastructure to bring the highest-quality products, rich in terpenes and cannabinoid content, to some of the best retail locations in the state starting Q1 2022.”

To view the full article, visit https://cnw.fm/kdb4V

About Red White & Bloom Brands Inc.

The company is positioning itself to be one of the top three multistate cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major U.S. markets with respect to cannabis and the U.S. and internationally for hemp-based CBD products. For more information about the company, visit www.RedWhiteBloom.com.

NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://cnw.fm/RWBYF

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Republican-Sponsored Bill Could Be Ideal Federal Cannabis Policy Reform Law

Democrats have generally been at the helm of cannabis reform, especially at the federal level. The most prominent cannabis bills, ones that would federally decriminalize cannabis and allow for federal cannabis taxes as well as give businesses in the cannabis space access to financial services have been helmed by Democrats. However, stakeholders have said that getting Republicans to pass comprehensive cannabis reform will be almost impossible, especially if it was prepared by the left. A new Republican-led marijuana bill may be the answer to this dilemma.

Led by Rep. Nancy Mae, the legislation titled the States Reform Act may be the compromise between the more modest marijuana reform that Republicans have proposed and the comprehensive cannabis reform Democrats would like to pass. The measure is currently being circulated among industry stakeholders to get feedback, with the final version being officially filed later this month.

If the bill receives enough support from the GOP, we may finally see Congress pass federal cannabis reform. Given that the bill champions the right of states to decide how they want to handle cannabis as well as the business interests of already existing cannabis firms, it is likely that the GOP may support the bill.

Through the States Reform Act, Mae, who was also the only Republican to vote in favor of a marijuana research bill for vets, is looking to deschedule cannabis at the federal level and create a regulatory framework while ensuring the new laws do not burden or undermine already existing state cannabis markets. A 3.75% excise tax would be used to fund grant programs for the Small Business Administration Program, community re-entry, law enforcement and aid for new cannabis businesses. Interstate commerce would be regulated by the Treasury Department’s Alcohol Tax and Trade Bureau (“TTB”) and the Food and Drug Administration (“FDA”) would have limited regulatory control over recreational cannabis.

Mae’s new 116-page cannabis legislation would cap access to recreational cannabis at 21 years to curb youth drug use as well as place certain limitations on marketing and advertising. Additionally, the bill would allow the expungement of the records of individuals with certain nonviolent federal cannabis convictions, provide protections for veterans who use cannabis and task the U.S. Department of Veterans Affairs (“VA”) with authorizing doctors to recommend medical marijuana for veterans. It is not yet clear if any other Republican lawmakers will be involved with the bill once it is officially unveiled.

As the push for federal drug-policy reform gains momentum, a time may come when marijuana is decriminalized and more patients would be able to use the cutting-edge devices designed to ease the use of cannabis medicines, such as the devices manufactured by RYAH Group Inc. (CSE: RYAH).

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — House Committee Approves Cannabis Research Measure for Veterans

Last week, the House Veterans’ Affairs Committee passed a measure that would mandate the Department of Veterans Affairs to carry out clinical trials on the therapeutic potential of cannabis for military veterans. The House committee approved the bill in an 18 to 11 vote.

The bill, dubbed the VA Medicinal Cannabis Research Act, would require the department to conduct studies on the use of medical cannabis in the treatment of chronic pain and post-traumatic stress disorder. Earlier versions of this measure had been introduced and cleared by the committee in 2018 and 2020. However, none was enacted into law.

In an interview, Rep. Lou Correa who sponsored the measure stated that Congress needed to explore alternative options for treatment such as marijuana, noting that not supporting the measure would defer the obligation that legislators had to care for those who had sacrificed a lot to protect the country.

David Carrol of the Department of Veterans Affairs stated that any clinical trials that involved human subjects and carried potential risks needed to use the smallest number of participants needed, in order to avoid putting them at needless risk. The representative explained that some effects of cannabis weren’t known, which is why, to ensure the validity of the research, a delimited approach that would determine best outcome measure, mode of administration and dosage had to be demonstrated in a proof-of-concept approach.

Additionally, Carrol argued that some requirements stated in the measure, such as studying different varieties of marijuana, weren’t consistent with the present state of scientific evidence, which suggested that smaller controlled clinical trials that had a focused set of objectives were ideal in determining proof of concept for using marijuana to treat various conditions.

In its legislative text, the measure lists both the optional and required elements of the trials, noting that when it comes to trials on chronic pain, the department would have to examine the effect of cannabis consumption on quality of sleep, inflammation, use of alcohol, benzodiazepine dosage and use, opioid dosage and use, osteopathic pain and quality of life.

With respect to post-traumatic stress disorder, the agency would also have to look at the extent to which marijuana impacted basic symptoms of the disorder, quality of sleep, suicidal ideation, social functioning, anxiety, mood, use of alcohol and the dosage and use of benzodiazepines.

In addition to this, the clinical trials could also assess the impact of the use of marijuana in treating PTSD and chronic pain on spasticity, neuropathy, cannabinoid hyperemesis syndrome, psychosis, mania, motor vehicle accidents, intestinal inflammation, different types of cancer, cardiovascular events and pulmonary function.

If this bill eventually becomes law, it will be easier for scientists to study various cannabis compounds and formulations, such as those manufactured by companies such as Simply Sonoma Inc. in order to ascertain the extent to which they possess medicinal benefits.

NOTE TO INVESTORS: The latest news and updates relating to Simply Sonoma Inc. are available in the company’s newsroom at https://cnw.fm/Sonoma

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Enters into Cannabinoid Science

Flora Growth Corp. (NASDAQ: FLGC) recently announced the next stage of its development with the creation of Flora Pharma and the execution of an agreement to begin scientific clinical trials globally. Flora Pharma’s formation follows the acknowledgment and commitment by the management team and board of directors to move ahead with applied research initiatives in medical cannabis in order to become a leader in the discovery, development, manufacturing and commercialization of novel, phytocannabinoid-based prescription medicines and nutraceutical products to address a broad range of diseases. The company also signed an agreement to begin scientific clinical trials on the use of cannabinoids to treat fibromyalgia and chronic pain, with the primary research sites for the global effort located in the U.S. and U.K. “Our team is incredibly excited to announce our entry into cannabinoid science,” president and CEO Luis Merchan was quoted in a recent article. “Commercial harvests are well underway, and it is now that we’re able to turn our attention to what we believe is the long-term future of our industry and to hedge ourselves further against the commoditization of raw cannabis materials.”

To view the full article, visit https://cnw.fm/xbrtt

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Why Cannabis Strategic Ventures Inc. (NUGS) Is ‘One to Watch’

Cannabis Strategic Ventures (OTCQB: NUGS), an emerging leader in the U.S. cannabis marketplace, is guided by the vision to acquire and scale assets in the legal cannabis market while achieving efficiencies through economies of scale and vertical integration. “Cannabis Strategic Ventures recently expanded its portfolio by completing the transfer process for cultivation, retail, distribution and manufacturing licenses issued by the city of Los Angeles and the state of California, and it is now working toward taking operational control of each license,” reads a recent article. Its brand portfolio includes NUGS, the NUGS Farm North and MDRN Tree. NUGS provides emerging and existing cannabis consumer brands with operational and financial strategic partnerships and various essential services. The NUGS Farm North brand operates a six-and-a-half-acre cannabis cultivation property in northern California, while MDRN Tree is Cannabis Strategic Ventures’ customer-facing dispensary brand. “The company also recently announced the upcoming grand opening of its cannabis dispensary, MDRN Tree. Following that launch, Cannabis Strategic Ventures intends to deploy another of its new licenses to establish an indoor cultivation facility with a capacity to produce two to three pounds of premium exotic flower per light, per harvest. The facility will have up to 1,200 grow lights and is anticipated to yield 5.75 harvests per year, bringing it to a total production capacity of over 15,000 pounds of cannabis flower annually.”

To view the full article, visit https://cnw.fm/7tjPJ

About Cannabis Strategic Ventures Inc.

Cannabis Strategic Ventures is one of the largest publicly traded marijuana cultivators in the United States. The company is Los Angeles-based and incubates, develops and partners with category leaders within the cannabis and ancillary sectors. The firm’s NUGS brand experience provides operational and financial strategic partnerships and a range of essential services to emerging and existing Cannabis consumer brands. For more information, visit www.CannabisStrategic.com.

NOTE TO INVESTORS: The latest news and updates relating to NUGS are available in the company’s newsroom at http://cnw.fm/NUGS

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — New Study Finds That Cannabis Legalization Decreases Racially Biased Arrests

New research has found that states which maintain cannabis prohibition continue seeing increases in disparities in rates of arrest while those that decriminalize or legalize cannabis experience significant reductions in race-based arrests. The research was published by the American Medical Association in its JAMA journal. The report examined data collected from 43 states in the country in order to establish a clear pattern.

The researchers from Saint Louis University and Eastern Virginia Medical School analyzed arrests between 2008 and 2019, with a focus on trends associated with race. They discovered that over that period of time, states which legalized marijuana saw a 190-person drop in arrests for Caucasian people and a 560-person decline in arrests per 100,000 African Americans.

With regard to decriminalization, the researchers found a 117-person decline in arrests for Caucasian individuals and about 450-person drop in arrests per 100,000 African Americans. The researchers also found that racial disparities in arrests dropped in states which enacted reform and rose in those that maintain prohibition, noting that rates of arrest increased for Black individuals and remained stable for their White counterparts. In addition, they found that data on cannabis arrests in adolescents shows that younger individuals faced a lower risk of being arrested under decriminalization in comparison with legalization.

In their report, the researchers explained that arrest trends showed almost no change in the rates of arrest of Black and White young people in states that had implemented marijuana legalization, which isn’t surprising, if one considers that young people aren’t included in the legalized market, as it targets people aged 21 and above. They note that despite this result, it is important to continue to monitor the effects of policy changes as well as advocate for targeted policies that address arrest disparities and youth arrests.

This research confirms that while arrests for White individuals remained almost the same, the arrest rate disparity increased over time for Black individuals in states that didn’t implement policy changes, which is what advocates of reform have argued for. In their conclusion, the researchers note that the study’s results called attention to the need for targeted interventions that address racial injustice.

This isn’t the first time marijuana policy and the racist effect of the drug war on Black people in the United States has been discussed or mentioned in studies. Nora Volkow, head of the National Institute on Drug Abuse, has on more than one occasion criticized and called attention to the racial disparities in the enforcement of drug criminalization.

When one sees these arrest disparities in jurisdictions with prohibitionist laws, a new appreciation of the deeper role legal cannabis companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) indirectly play by promoting equity comes to light.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — The EU Legalizes CBD as Cosmetics Ingredient

Despite the CBD industry’s runaway success in the past couple of years, the sector’s position in several territories is tenuous at best. A relatively new product, cannabidiol (“CBD”) has attracted a ton of consumer attention thanks to claims of its medical efficacy. However, experts say that the hype has outpaced science because there is limited research into the possible benefits and risks of CBD. Furthermore, the European Cosmetic Regulation 1224/2009 prohibits the use of cannabis and its extracts in cosmetics. European authorities have been quite strict against firms in the CBD space as a result, passing policies such as the ban on using cannabis extracts such as cannabidiol in cosmetics.

Fortunately for players interested in entering the CBD cosmetics segment, the EU has legalized the use of cannabidiol as an ingredient in cosmetics. This February, the EU’s directorate-general for internal market, industry, entrepreneurship and SMEs added CBD to the list of legal cosmetic ingredients its Cosing guidelines. This is a cosmetic regulations database that lists authorized and outlawed cosmetic ingredients as well as their uses and functions. With this addition, CBD companies that choose to develop CBD-infused cosmetics can do so without fear of persecution from the authorities.

The CBD cosmetics segment has been on the rise for the past couple of years. Studies have found that CBD has anti-inflammatory and antioxidant properties that make it effective at treating skin conditions, including breakouts, acne, eczema and psoriasis. The global CBD cosmetics market was estimated to be worth $633.6 million in 2018, and it is projected to hit a whopping $1.7 billion by 2025 due to increased awareness of the healing power of CBD cosmetics. Demand for CBD, in general, has been on the rise in Europe, and the European CBD market is projected to grow by 400% over the next couple of years.

CBD’s addition to the EU’s list of legal cosmetic ingredients came after the European Industrial Hemp Association, a transnational organization that promotes the objectives of European industrial hemp entrepreneurs, submitted a proposal to the EU asking it to add CBD to the Cosing database. The organization also asked for the inclusion of a trio of new International Nomenclature Cosmetic Ingredient (“INCI”) names — root extracts from Cannabis Sativa, leaf/stem extracts from cannabis sativa and leaf extracts from Cannabis Sativa — as well as the removal of Cannabis Sativa L restrictions.

The infamous Kanavape Case was also partly responsible for CBD’s entry into the Cosing guidelines. Two French businessmen found themselves facing charges when they imported and marketed CBD oil extracted from hemp biomass with the aim of using it in e-cigarettes. Although their actions were in line with EU laws allowing the free movement of goods between member states, national law only allowed CBD that was extracted from hemp fiber and seeds. The court ruled that this French law was at odds with EU regulations and had a similar effect to restrictions on imports.

With this legalization of the use of CBD in cosmetics within the EU bloc, companies such as Flora Growth Corp. (NASDAQ: FLGC) that have beauty products containing cannabidiol could see major bursts of growth as they enter the European market.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom athttps://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – IBN Announces Collaboration for Upcoming Lift&Co. Expo

IBN (“InvestorBrandNetwork”), an innovative corporate communications firm and content distributor, today announced that it will serve as media sponsor for the Lift&Co. Expo. Well-known for becoming Canada’s biggest event for cannabis consumers, industry professionals, investors and the media, this year’s Lift&Co. Expo is set to take place at Toronto’s Metro Toronto Convention on Nov. 18-21, 2021. Returning in an in-person format, the event will feature upwards of 250 exhibitors from around the world and bring together Canada’s top business leaders, innovators and regulators to share their perspectives and approaches on the most important issues facing Canada’s cannabis business sector. In its capacity as the event’s media sponsor, IBN will work to further the distribution and publication of content generated for the event.

To view the full press release, visit https://cnw.fm/ZJ683

About IBN

IBN (“InvestorBrandNetwork”) consists of financial brands introduced to the investment public over the course of 15+ years.

With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

CannabisNewsWire (“CNW”) , one of 50+ brands within our InvestorBrandNetwork (“IBN”), is a specialized information service that (1) aggregates cannabis news; (2) provides CannabisNewsBreaks to quickly update investors in the space; (3) enhances corporate press releases; (4) provides social media distribution via IBN to 2+ million likes and followers; and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of 5,000+ key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only).

For more information, please visit https://www.InvestorBrandNetwork.com.

Please see full terms of use and disclaimers on IBN’s website, applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs for 2022. According to the update, the studies mentioned in the announcement represent only a fraction of Lexaria’s 2022 work programs. “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease and diabetes.” To view the full press release, visit https://cnw.fm/VCto4 About Lexaria Bioscience Corp. Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CannabisNewsWire (CNW) Denver, Colorado www.CannabisNewsWire.com 303.498.7722 Office Editor@CannabisNewsWire.com CannabisNewsWire is part of the InvestorBrandNetwork.